Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

GD2-CAR-NK in combination with Smac Mimetics: A Novel Therapeutic Strategy Against High-Risk Neuroblastoma

FY 2021-22

Summary
Neuroblastoma (NB) is the second most common pediatric solid tumor cancer of immature nerve cells. NB tumors have a diverse range of clinical behaviors, from spontaneous regression in infants under 24 months to a highly recurrent and aggressive malignancy in children older than 24 months.The current therapies for high-risk NB are multi-modal, involving surgery, radiation, and high-dose combination chemotherapy. These therapies carry significant harmful side effects, such as neurological and developmental problems. Furthermore, high-risk NB patients tend to resist these treatments and have a higher chance of tumor recurrence. Therefore, it is imperative to invest in developing new targeted therapeutics against high-risk NB that improve clinical outcomes and patient quality of life. I aim to combine two different current treatment techniques that capitalize on the cytotoxic activity of NK cells along with the specific antibody-mediated recognition of NB cells. I will also use a family of experimental cancer drugs called SMAC mimetics to increase NK cytotoxicity and persistence, which are common issues faced with these types of treatments. I plan to ensure the safety and efficacy of the therapeutic in animal and neuroblastoma models, providing an improved targeted tool to fight high-risk NB tumors.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
467077
Name
Hakoum Mariam
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
GD2-CAR-NK in combination with Smac Mimetics: A Novel Therapeutic Strategy Against High-Risk Neuroblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cancer Therapy; Car-Nk; Combination Therapy; Immune Response; Immune Stimulation; Immunotherapy; Neuroblastoma; Pediatric Cancer; Smac Mimetics
Abstract
Neuroblastoma (NB) is the second most common pediatric solid tumor cancer of immature nerve cells. NB tumors have a diverse range of clinical behaviors, from spontaneous regression in infants under 24 months to a highly recurrent and aggressive malignancy in children older than 24 months.The current therapies for high-risk NB are multi-modal, involving surgery, radiation, and high-dose combination chemotherapy. These therapies carry significant harmful side effects, such as neurological and developmental problems. Furthermore, high-risk NB patients tend to resist these treatments and have a higher chance of tumor recurrence. Therefore, it is imperative to invest in developing new targeted therapeutics against high-risk NB that improve clinical outcomes and patient quality of life. I aim to combine two different current treatment techniques that capitalize on the cytotoxic activity of NK cells along with the specific antibody-mediated recognition of NB cells. I will also use a family of experimental cancer drugs called SMAC mimetics to increase NK cytotoxicity and persistence, which are common issues faced with these types of treatments. I plan to ensure the safety and efficacy of the therapeutic in animal and neuroblastoma models, providing an improved targeted tool to fight high-risk NB tumors.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hakoum, Mariam
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~